Clinical Trials

8 enrolled

CNS

Glioma

NCT06073730 2023-10-10

Viale-a

154 enrolled

Leukemia, Myeloid, Acute

NCT05949762 2023-07-18

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

45 enrolled

Leukemia, Myeloid, Acute

NCT05140811 2023-05-24

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

126 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05805072 2023-05-06

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

20 enrolled

Leukemia, Myeloid, Acute

NCT05823701 2023-04-21

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

23 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT05772728 2023-03-16

Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)

23 enrolled

Lymphoma, T-Cell

NCT04809181 2023-02-21

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

95 enrolled

Recurrence, Hematologic Neoplasms

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

116 enrolled

Lymphoma, T-Cell, Peripheral

NCT04913922 2022-11-08

AARON

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

13 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04248595 2022-09-08

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

100 enrolled

Leukemia, Myeloid, Acute

NCT04687761 2022-09-08

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

84 enrolled

Leukemia, Myeloid, Acute

NCT05457361 2022-07-14

VAH Versus VA for Salvage Therapy of R/R-AML

162 enrolled

Leukemia, Myeloid, Acute

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05053425 2022-04-26

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Leukemia, Myeloid, Acute

NCT05042531 2022-04-25

Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT04480125 2022-04-20

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

28 enrolled

Lymphoma, T-Cell, Peripheral

NCT04490707 2022-03-24

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

60 enrolled

Leukemia, Myeloid, Acute

NCT05282719 2022-03-16

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

33 enrolled

Myeloid

Myelodysplastic-Myeloproliferative Diseases

NCT03873311 2022-03-15

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Phase 4 Unknown

114 enrolled

Leukemia, Myeloid, Acute

NCT05262465 2022-03-02

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

300 enrolled

Leukemia, Myeloid, Acute

NCT05175508 2022-01-03

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Phase 2/3 Unknown

180 enrolled

Frailty, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

37 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02124174 2021-04-26

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Classical hematologyMyeloidOther hematologic neoplasm

50 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04052659 2021-03-09

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Lymphoma, T-Cell, Peripheral

NCT04454580 2020-09-16

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Unknown

15 enrolled

Leukemia, Myeloid, Acute

NCT04541277 2020-09-09

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

55 enrolled

Leukemia, Myeloid, Acute

NCT03588078 2020-01-30

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

53 enrolled

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

NCT03719989 2018-10-25

EPIC

27 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02489929 2015-07-03

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

35 enrolled